Tractament del carcinoma de cèl·lules renals avançat en segona línia: informe d’avaluació de resultats
Abstract
The data reported by prescribers have been selected for patients who have been treated in the Integral Health System of Catalonia (SISCAT) with axitinib, cabozantinib (anti-VEGF), nivolumab (anti-PDL1) or everolimus (mTOR inhibitors) and were included in the CatSalut Register of Patients and Treatments (RPT) between January 2013 and April 2021. About 78% of the patients analyzed met the clinical criteria for treatment established in the harmonization agreement and the 12 months of follow-up more than 28% of treated patients had not progressed and about 45% of patients were still alive.
Keywords
Advanced renal cell carcinoma; Tyrosine kinase inhibitors; MTOR inhibitors; Immunotherapy; Health results
Bibliographic citation
Programa d'Harmonització Farmacoterapèutica. Tractament del carcinoma de cèl·lules renals avançat en segona línia: informe d’avaluació de resultats. Barcelona: Servei Català de la Salut; 2021.
Audience
Professionals
Use this identifier for quote and/or link this document
https://hdl.handle.net/11351/6526This item appears in following collections
The following license files are associated with this item: